Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul class="summary-list"><li><keyword id="3103584" type="PERSON" weightage="60" keywordseo="CureVac">CureVac</keyword> lost more than half its value after its <keyword id="8763838" type="UNKNOWN" weightage="60" keywordseo="covid-19">COVID-19</keyword> <keyword id="24209" type="PERSON" weightage="60" keywordseo="vaccine">vaccine</keyword> jab showed 47% effectiveness.</li><li>Results were based on <keyword id="83911" type="ORGANIZATION" weightage="60" keywordseo="Clinical-trials">clinical trials</keyword> conducted in Latin America and Europe on about 40,000 volunteers.</li><li>The company attributed its results to 29 virus strains in the 10 countries where its trials took place. </li></ul><a href="https://markets.businessinsider.com/stocks/cvac-stock">CureVac's</a> shares tumbled by as much as 50% on Thursday after the German pharmaceutical firm said its <a href="https://www.businessinsider.com/curevac-vaccine-efficacy-late-stage-trial-covid-bill-gates-2021-4">COVID-19 vaccine candidate failed</a> in a <keyword id="122283" type="PERSON" weightage="60" keywordseo="Clinical-trial">clinical trial</keyword>.Interim analysis of data from about 40,000 volunteers showed the biotech's jab is only 47% effective, falling short of the study's criteria and the minimum <a href="https://www.nbcnews.com/health/health-news/fda-s-cutoff-covid-19-vaccine-effectiveness-50-percent-what-n1245506">50% effectiveness threshold</a> required by US regulators.Data for the late-stage clinical trials that were conducted in Latin America and Europe was released after the US close on Wednesday. The company, backed by the Bill &amp; Melinda Gates Foundation, attributed its disappointing results to the fact there are at least 29 COVID-19 strains circulating in the 10 countries where its trials took place.The Gates foundation owns about 1.7% of CureVac, or 3.1 million shares, according to Bloomberg.CureVac's US shares are listed on the Nasdaq and plunged after hours from $94.79 at Wednesday's close to $49.54 at Thursday's market open.The 47% efficacy estimate is based on 134 COVID-cases that occurred at least two weeks after the administration of the second dose, the company <a href="https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/">said in a statement</a>."While we were hoping for a stronger interim outcome, we recognize that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging," CureVac CEO Franz-Werner Haas said.CureVac said last year that it was working with <a href="https://markets.businessinsider.com/stocks/tsla-stock">Tesla</a> on a vaccine printer, which <a href="https://www.bloomberg.com/news/articles/2021-04-10/curevac-could-win-covid-shot-approval-in-may-augsburger-says">Elon Musk reportedly called</a> "an important product for the world." Musk said in a tweet about the biotech in April that it "sounds like they're a few months away from regulatory approval." This tweet was later deleted.The company will continue trials of its two-dose messenger RNA vaccine and expects to publish final analysis within the next few weeks.Read More: <a href="https://www.businessinsider.com/investing-strategy-advice-playbook-stocks-commodities-crypto-after-fed-meeting-2021-6" target="_blank" rel="noopener noreferrer">The Fed has left rates steady while signaling 2 potential hikes by the end of 2023. Here is what to do with your stocks, bonds, and digital assets, according to top Wall Street and crypto investors.</a>

German biotech CureVac's stock plunges 50% after its COVID-19 vaccine candidate failed a clinical trial

<ul><li><a href="https://markets.businessinsider.com/stocks/cvac-stock">CureVac</a>, a German biotech backed by Bill Gates, said Thursday it is in talks with the EU to supply 225 million doses of its <a href="https://www.curevac.com/en/2020/08/20/curevac-and-european-commission-in-advanced-discussions-to-supply-up-to-405-million-doses-of-potential-mrna-based-covid-19-vaccine/">potential coronavirus vaccine. </a></li><li>Shares of <keyword id="3103584" type="PERSON" weightage="60" keywordseo="CureVac">CureVac</keyword> jumped more than 18% in premarket trading on Thursday. </li><li>If an agreement is reached, it would mark the company's first bilateral supply deal, <a href="https://www.reuters.com/article/us-health-coronavirus-eu-curevac/eu-curevac-in-advanced-talks-for-225-million-covid-19-vaccine-doses-idUSKBN25G0Z2">according to Reuters</a>.</li><li><a href="https://markets.businessinsider.com/stocks/cvac-stock">Watch CureVac trade live on Markets Insider</a>.</li><li><a href="https://www.businessinsider.com/">Read more on Business Insider</a>.</li></ul>Shares of <a href="https://markets.businessinsider.com/news/stocks/curevac-stock-price-since-ipo-bill-gates-coronavirus-vaccine-german-2020-8-1029510118#">CureVac</a>, a German biotech firm backed by Bill Gates, surged as much as 18% in premarket trading Thursday after the company said it is in talks with the European Commission to supply doses of its potential <keyword id="8624004" type="UNKNOWN" weightage="60" keywordseo="coronavirus-vaccine">coronavirus vaccine</keyword>. The potential contract with the European Commission intends to provide European Union member states with up to 225 million doses of the <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> vaccine, once it has been proven safe and effective against <keyword id="8763838" type="UNKNOWN" weightage="60" keywordseo="covid-19">COVID-19</keyword>, the <a href="https://www.curevac.com/en/2020/08/20/curevac-and-european-commission-in-advanced-discussions-to-supply-up-to-405-million-doses-of-potential-mrna-based-covid-19-vaccine/">company said in a press release</a>.Read more: <a href="https://www.businessinsider.com/stock-picks-to-buy-back-to-school-big-returns-jefferies-2020-8">Jefferies says buy these 7 back-to-school stocks poised for big returns with much of the US going remote</a>The contract would also give the European Commission the option to purchase an additional 180 million doses, bringing the total to 405 million doses of the potential vaccine. If an agreement is reached, it would mark the company's first bilateral supply deal, <a href="https://www.reuters.com/article/us-health-coronavirus-eu-curevac/eu-curevac-in-advanced-talks-for-225-million-covid-19-vaccine-doses-idUSKBN25G0Z2">according to Reuters.</a>CureVac's mRNA-based COVID-19 vaccine candidate is currently in a Phase 1 clinical trial at different sites in Germany and Belgium, aiming to determine safety and efficacy of the drug in humans, the company said. It expects to have results from the trial early in the fourth quarter of 2020, and move to the next phase soon after. CureVac has gained more than 255% since <a href="https://markets.businessinsider.com/news/stocks/curevac-stock-price-since-ipo-bill-gates-coronavirus-vaccine-german-2020-8-1029510118#">its recent public trading</a> debut <a href="https://markets.businessinsider.com/stocks/cvac-stock">through Wednesday's close.</a><a href="https://markets.businessinsider.com/stocks/cvac-stock"><div type="image" title="Screen Shot 2020 08 20 at 8.29.35 AM" height="1160" width="1554" msid="77656423" hostid="261"></div></a>

Bill Gates-backed CureVac jumps 18% on report it's in advanced talks with the EU for 225 million doses of its potential COVID-19 vaccine

<ul><li><a href="https://markets.businessinsider.com/stocks/cvac-stock">CureVac,</a> a German biotechnology company, skyrocketed in its initial public offering on Friday, raising $213.3 million and more than tripling from its IPO price. </li><li>Shares of the company have continued to surge since its Friday IPO, gaining as much as 52% to $85 per share on Monday — a 431% jump from the company's $16 IPO price. </li><li>The company is backed by billionaire Microsoft founder <keyword id="45830" type="PERSON" weightage="60" keywordseo="Bill-Gates">Bill Gates</keyword> and is working on a potential <keyword id="8624004" type="UNKNOWN" weightage="60" keywordseo="coronavirus-vaccine">coronavirus vaccine</keyword>. </li><li><a href="https://markets.businessinsider.com/stocks/cvac-stock">Watch CureVac trade live on Markets Insider</a>.</li><li><a href="https://www.businessinsider.com/">Read more on Business Insider</a>.</li></ul><a href="https://markets.businessinsider.com/stocks/cvac-stock">CureVac</a>, a German biotechnology company, has skyrocketed as much as 431% since its initial public offering on Friday. The company is backed by Microsoft founder and billionaire Bill Gates, and is working on a potential vaccine for <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword>. On Friday, it raised $213.3 million in its IPO, <a href="https://www.marketwatch.com/story/curevac-raises-2133-million-in-ipo-after-pricing-at-16-a-share-high-end-of-proposed-range-2020-08-14?mod=article_inline">pricing at $16 per share, the high end of its expected range</a>.In its public trading debut, shares more than tripled, ending the day up 249% at $55.90 per share. On Monday, the biotech company's epic rally continued as shares surged as much as 52% to reach an all-time high of $85 per share. Read more: <a href="https://www.businessinsider.com/stocks-to-buy-3-companies-boom-from-covid-vaccine-schwab-2020-8">Charles Schwab's stock-picking chief told us why a COVID-19 vaccine would trigger a mass exit from tech stocks — and pinpoints 3 companies that would benefit instead</a><keyword id="3103584" type="PERSON" weightage="60" keywordseo="CureVac">CureVac</keyword> <a href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920095636/tm2016252-23_424b4.htm">said in a regulatory filing</a> that it will use the proceeds from its IPO for research and development, expanding its manufacturing capabilities, and to fund the clinical development of its potential coronavirus vaccine through the completion of its Phase 3 trial.The company in June started its Phase 1 coronavirus vaccine trial with healthy human participants, and expects results in the fourth quarter of the year, according to the <a href="https://www.sec.gov/Archives/edgar/data/1809122/000110465920095636/tm2016252-23_424b4.htm">SEC filing.</a> In addition to the coronavirus, CureVac is working on vaccines for rabies and other infectious diseases as well as treatments for tumors, cancers, and other diseases. "Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs," the company said in the filing. <a href="https://markets.businessinsider.com/stocks/cvac-stock"><div type="image" title="Screen Shot 2020 08 17 at 2.17.41 PM" height="928" width="1558" msid="77600542" hostid="261"></div></a>

This Bill Gates-backed coronavirus vaccine developer has skyrocketed 431% in just 2 days after going public

<ul class="summary-list"><li><keyword id="3103584" type="PERSON" weightage="60" keywordseo="CureVac">CureVac</keyword>'s experimental COVID-19 <keyword id="24209" type="PERSON" weightage="60" keywordseo="vaccine">vaccine</keyword> failed in a pivotal clinical study, the <keyword id="45082" type="PERSON" weightage="60" keywordseo="biotech">biotech</keyword> said Wednesday.</li><li>It's the first late-stage study to flop, with CureVac's vaccine showing 47% effectiveness. </li><li>The German biotech saw its stock price drop by more than 50% in post-market trading. </li></ul>A COVID-19 vaccine candidate developed by the <a href="https://www.businessinsider.com/curevac-ceo-interview-coronavirus-vaccine-development-germany-trump-controversy-2020-3" target="_blank" rel="noopener">German biotech CureVac</a> failed in a critical late-stage study, the company said Wednesday.It's the first failure of a major vaccine candidate in a final-stage trial. CureVac said an interim analysis showed the shot was 47% effective, falling short of the study's goals and the minimum bar for what US regulators find approvable.The development is a setback to the world's immunization efforts, as European officials had previously reached deals to acquire up to 405 million doses of the shot. Despite the disappointing result, CureVac CEO Franz-Werner Haas said the company plans to go "full speed for the final readout." The trial is still ongoing and the final vaccine efficacy figure may vary as more COVID-19 cases are tallied. "We are still planning for filing for approval," Haas <a href="https://www.nytimes.com/2021/06/16/health/curevac-vaccine.html">told The New York Times' Carl Zimmer</a>.CureVac, which is backed by The Bill &amp; Melinda Gates Foundation, saw its stock price plummet following Wednesday's announcement. Shares were down more than 50% in post-market trading. The foundation owns about 3.1 million shares of CureVac, or 1.7% of the company, according to data compiled by Bloomberg.An independent biostatistics expert said it will be nearly impossible for CureVac's study to still produce success. The 47% estimate of efficacy is based on 134 COVID-19 cases among study participants. "It's not going to change dramatically," Natalie Dean, a University of Florida biostatistician, <a href="https://www.nytimes.com/2021/06/16/health/curevac-vaccine.html">told The Times</a>.<h2>CureVac blames variants, even as other vaccines hold up against different strains</h2>In a statement, CureVac leaders said that the abundance of virus variants played a role in the result. Only one of the 134 analyzed cases resulted from the original strain of the SARS-CoV-2 virus, the company said. "While we were hoping for a stronger interim outcome, we recognize that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging," CureVac CEO Franz-Werner Haas said in a statement.The disappointing result is surprising given some of the similarities CureVac's experimental vaccine candidate had with other, highly effective immunizations. CureVac's shot is a messenger RNA vaccine, a new technology platform that's also used by Moderna and Pfizer-BioNTech. Those shots proved to be more than 90% effective in late-stage trials last year. They also appear to <a href="https://www.businessinsider.com/covid-19-vaccine-efficacy-variants-india-south-africa-brazil-uk-2021-5">protect people against</a> some major virus variants.Other vaccines have also shown success against variants. Novavax, for instance, announced earlier this week its two-dose shot <a href="https://www.businessinsider.com/novavax-covid-19-vaccine-us-clinical-trial-results-2021-4">was 90% effective in a late-stage study</a>. What's more, Novavax's vaccine was about 93% effective in preventing illnesses caused by variants of concern or variants of interest, the company said.<h2>A quiet existence, until the pandemic</h2>Since its founding in 2000, CureVac had a largely quiet existence until the pandemic. As one of the first companies trying to develop a COVID-19 vaccine, CureVac's CEO was invited to the White House in March 2020. Shortly after, reports <a href="https://www.businessinsider.com/curevac-coronavirus-vaccine-trump-germany-denial-2020-3">circulated</a> that the US had offered a "large sum" for access to its vaccine program. <a href="https://www.businessinsider.com/curevac-coronavirus-vaccine-trump-germany-denial-2020-3">CureVac disputed the reports</a>. The company also cycled through three CEOs in the span of a week.Tesla CEO Elon Musk has also drawn attention to CureVac with his <a href="https://www.bloomberg.com/news/articles/2021-04-09/musk-deletes-tweet-speculating-on-curevac-s-vaccine-approval">tweets</a>. A Tesla subsidiary is <a href="https://www.businessinsider.com/tesla-building-microfactories-with-coronavirus-vaccine-maker-curevac-2020-7">working with CureVac</a> in building a "prototype of an automated manufacturing unit," Insider reported in July.In its Wednesday press release, CureVac focused attention on its second-generation <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> vaccine. Pharma giant GlaxoSmithKline has partnered with CureVac on that research, paying the company roughly $235 million upfront and investing an additional $180 million in <a href="https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/">multiple</a> <a href="https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-announce-strategic-mrna-technology-collaboration/">deals</a> over the past year.CureVac said it hopes this next-generation program could start human testing by the end of September, with the goal of launching in 2022.Dr. Catherine Schuster-Bruce contributed reporting.

CureVac's COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotech

<ul><li>German vaccine maker CureVac said that interim results from early trials showed CvnCoV triggered immune response among volunteers. </li><li>Israel began <a href="https://www.businessinsider.in/science/health/news/israel-begins-human-trials-on-covid-19-vaccine/articleshow/78991044.cms?upcache=2">human trials</a> of a COVID-19 vaccine on November 1. </li><li>South African pharmaceutical giant Aspen Pharmacare signed a pact with Johnson &amp; Johnson to manufacture its Covid-19 vaccine.</li></ul>After registering over 42 million COVID-19 infections, the World Health Organisation is <a href="https://www.livemint.com/science/health/who-expects-to-see-covid-19-vaccine-by-end-of-2020-at-earliest-11602548070399.html">finally expecting</a> a COVID-19 vaccine by the end of 2020 or early 2021. It takes a decade or two to design, test, and launch an effective vaccine that can protect billions of people from diseases. However, COVID-19 has forced researchers to fast-track the vaccine making process. Here's a look at COVID-19 vaccine updates from around the world — Bharat Biotech to launch Covaxin by mid-2021 Bharat Biotech is planning to launch India's indigenous COVID vaccine, Covaxin, in the second quarter of next year, after it gets the necessary approvals from regulatory authorities, reported <a href="https://in.reuters.com/article/health-coronavirus-india-vaccine/bharat-biotech-plans-to-launch-vaccine-candidate-in-second-quarter-of-2021-idINKBN27H1JG">Reuters</a>. The company is planning to begin recruitment for the third phase of its vaccine trials this month. The trial will be conducted in 25 sites in 10-12 states and will provide two doses with each for the vaccine and placebo recipients, the company's Executive Director Sai Prasad said. Germany CureVac's vaccine triggers an immune response On Monday, German vaccine maker CureVac said that interim results from early trials showed that its investigational Covid-19 vaccine candidate, CvnCoV, appeared safe and triggered immune response among volunteers. "We are very encouraged by the interim Phase 1 data. It represents a critical milestone in our Covid-19 vaccine programme and strongly supports the advancement of our vaccine candidate," Franz-Werner Haas, Chief Executive Officer of CureVac, said in a statement. Aspen Pharmacare, Johnson &amp; Johnson announce a deal to make Covid-19 vaccine South African pharmaceutical giant Aspen Pharmacare signed a pact with Johnson &amp; Johnson to manufacture its Covid-19 vaccine if approved in South Africa and internationally. In a statement, Aspen said that if ongoing trials bring international health authorities to endorse the J&amp;J vaccine as effective and safe, it would be produced at Aspen's manufacturing facility in Port Elizabeth in South Africa's Eastern Cape province. Moderna prepares for the global launch of COVID-19 vaccine American biotechnology company Moderna announced that it was preparing for the global launch of its Covid-19 vaccine candidate. "We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world," Xinhua news agency quoted Moderna CEO Stephane Bancel as saying in a statement on Thursday. In addition to the Phase 3 study of the Covid-19 vaccine mRNA-1273, which is fully enrolled, Moderna now has four programs in Phase 2 studies, according to Bancel. Israel begins human trials of COVID vaccine Israel has begun <a href="https://www.businessinsider.in/science/health/news/israel-begins-human-trials-on-covid-19-vaccine/articleshow/78991044.cms?upcache=2">human trials</a> of a COVID-19 vaccine on November 1, authorities have said. Two volunteers have received the vaccine. Israel will first test the vaccine on 80 people, before extending it to 980 in the second phase, and then 25,000 in the final stage, slated for April or May. "We can see the light at the end of the tunnel," Prime Minister Benjamin Netanyahu told reporters at Sheba Medical Center near Tel Aviv. Japan’s Shionogi is planning to conduct clinical trials of COVID-19 vaccine in December Japan’s Shionogi is planning to conduct phase I clinical trials of its COVID-19 vaccine candidate in December and phase II trials in January. Moreover, Shionogi S phase III trials are likely to be done overseas “due to the relative lack of COVID-19 cases in Japan”, reported Reuters. Brazil says it might get a COVID-19 vaccine by June 2021 Brazil is expected to have a COVID-19 vaccine <a href="https://zeenews.india.com/world/brazil-will-have-a-covid-19-vaccine-by-june-2021-says-regulator-2321092.html">ready </a>by June next year, according to the head of Brazil’s health regulator Anvisa, Antonio Barra Torres. According to Reuters, Anvisa is yet to decide on the minimum efficacy required to give vaccine approval. However, the agency has approved the vaccine with less than 50% effectiveness previously. Brazil has played a significant role in conducting late-stage clinical trials of many global vaccine candidates including Oxford-AstraZeneca. Oxford-AstraZeneca’s COVID-19 vaccine triggers an immune response in both young and old adults. Oxford-AstraZeneca’s COVID-19 vaccine candidate has <a href="https://in.reuters.com/article/health-coronavirus-astrazeneca-vaccine-i/oxford-covid-19-vaccine-prompts-immune-response-among-adults-old-and-young-astrazeneca-says-idUSKBN27B0L7">prompted </a>an immune response in both young and old adults. According to AstraZeneca, the vaccine also produces ‘lower adverse responses among elderly,” reported Reuters. “It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesman said. Pfizer recruits 42,000 volunteers for phase II and III clinical trials. US drugmaker Pfizer — which is working on a COVID-19 vaccine with German pharma company BioNTech — has <a href="https://www.indiatoday.in/coronavirus-outbreak/story/coronavirus-vaccine-update-oxford-astrazeneca-vaccine-immune-response-pfizer-covaxin-news-1735407-2020-10-27">recruited </a>42,111 volunteers to test its experimental COVID-19 vaccine candidate. Earlier this week, Pfizer said it is likely to submit its COVID-19 vaccine to the Food and Drug Administration (FDA) approval in November if the trials are successful. Joe Biden pledges free COVID-19 vaccines for all Americans if elected. Democratic presidential nominee Joe Biden, on October 24, has said that if he is elected to power in the November 3 election, he will make COVID-19 vaccines free for all Americans. "Once we have a safe and effective vaccine, it has to be free to everyone -- whether or not you're insured," Xinhua news agency quoted Biden as saying during a speech in Wilmington, Delaware. Johnson &amp; Johnson pauses late-stage COVID-19 trials following a participant’s illness A late-stage study of Johnson &amp; Johnson's COVID-19 vaccine candidate has been paused while the company investigates whether a study participant's unexplained illness is related to the shot. In a statement, the company said that illnesses, accidents and other so-called adverse events are an expected part of any clinical study, especially large studies, but that its physicians and a safety monitoring panel would try to determine what might have caused the illness. The pause is at least the second such hold to occur among several vaccines that have reached large-scale final tests in the US. The company declined to reveal any more details about the illness, citing the participant's privacy. Russia’s COVID-19 vaccine to be widely domestically available by early November Russia is all set to launch its COVID-19 vaccine, Sputnik V, domestically by late October or early November, according to the Russian Direct Investment Fund (RDIF). Earlier in August, Russia claimed to be the first country to develop a <keyword id="8624004" type="UNKNOWN" weightage="20" keywordseo="coronavirus-vaccine">coronavirus vaccine</keyword>. "We believe that the vaccine can start being widely used in Russia by late October or early November," Kirill Dmitriev, head, RDIF said. It is further expecting to roll out the vaccine in the Middle-East after human trials by the end of November, <a href="https://tass.com/society/1211423">Russian news agency TASS reported. </a> Pakistan hopes to acquire a COVID-19 vaccine within the next 6 months A Pakistani official from the Ministry of National Health Services has expressed hope that the country would acquire a vaccine against the novel coronavirus in the next six months. The official said on October 12 that Pakistan has also prepared antibodies against spike proteins, <a href="https://www.dawn.com/news/1584505/covid-positivity-rate-crosses-2pc-first-time-in-six-weeks">Dawn reported.</a> "At present, 15 vaccines were in phase-III trials globally out of which 11 target the spike protein," he said. UK to begin trials to test if anti-TB BCG vaccine works against COVID-19 Scientists in the United Kingdom will begin recruiting frontline healthcare workers to test if an old vaccine used to combat tuberculosis (TB), the Bacillus Calmette-Guerin, or BCG jab can be repurposed to help boost immunity against the novel coronavirus as well. The University of Exeter in south-west England said on October 11 that it is leading the UK arm of the worldwide research called the BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trials. Participants will be given either the BCG vaccine, currently provided to more than 100 million babies worldwide each year, including in India, to protect against TB or a placebo injection. In India, Bharat Biotech asked to submit complete phase 2 trial data of its COVID-19 vaccine before phase 3 trials On October 10, Bharat Biotech — which earlier got permission to conduct phase-3 clinical trials of its COVID-19 vaccine candidate — has been asked to submit complete safety and immunogenicity data of the ongoing phase-2 trial, besides providing some clarifications, before proceeding for the next stage. The vaccine candidate, 'Covaxin,' is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). According to officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase III randomised, double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate. SEE ALSO:<a href="https://www.businessinsider.in/thelife/personalities/news/prajakta-koli-aka-mostlysane-advice-for-content-creators-on-the-fine-line-between-brand-collaborations-and-staying-honest-on-social-media/articleshow/79013162.cms" data-type="tilCustomLink"> Prajakta Koli aka MostlySane’s advice for content creators on the fine line between brand collaborations and staying honest on social media</a> <a href="https://www.businessinsider.in/stock-market/news/top-stock-movers-tata-motors-zee-entertainment-icici-bank-cadila-healthcare-sterlite-technologies-and-others/articleshow/79012842.cms" data-type="tilCustomLink">Top stock movers — Tata Motors, Zee Entertainment, ICICI Bank, Cadila Healthcare, Sterlite Technologies and others</a> <a href="https://www.businessinsider.in/international/news/india-hits-out-at-pakistan-for-taking-advantage-of-coronavirus-pandemic-to-enhance-cross-border-terrorism/articleshow/79013307.cms" data-type="tilCustomLink">India hits out at Pakistan for taking advantage of coronavirus pandemic to enhance cross-border terrorism</a>

COVID-19 vaccine tracker: German CureVac shows an immune response, Aspen Pharmacare and J&J sign pact to make vaccine in South Africa

<ul class="summary-list"><li>US stocks were mixed Thursday as investors weighed the <keyword id="45672" type="ORGANIZATION" weightage="60" keywordseo="Fed">Fed</keyword>'s accelerated interest-rate hike guidance.</li><li>Weekly jobless claims came in at an unadjusted 412,000 last week, according to the Labor Department.</li><li><keyword id="6354947" type="UNKNOWN" weightage="60" keywordseo="bitcoin">Bitcoin</keyword> edged lower, while <keyword id="18712" type="ENTERTAINMENT" weightage="60" keywordseo="Gold">gold</keyword> and <keyword id="6359072" type="UNKNOWN" weightage="60" keywordseo="oil">oil</keyword> also tumbled.</li></ul>US stocks traded mixed on Thursday as investors digested the <keyword id="6355253" type="UNKNOWN" weightage="60" keywordseo="federal-reserve">Federal Reserve</keyword>'s accelerated interest-rate hike guidance.Based on new projections from the Federal Open Market Committee, the central bank <a href="https://www.businessinsider.com/federal-reserve-interest-rate-projections-fomc-june-inflation-monetary-policy-2021-6">will raise its benchmark interest rate two times in 2023</a>, compared to a prediction at its March meeting of zero rate hikes for the same period.The Fed had previously placed its first forecasted rate hikes past 2023, suggesting it was willing to let <keyword id="22195" type="COMPANY" weightage="60" keywordseo="Inflation">inflation</keyword> run hot to let the US economy recover. "Our preferred explanation is that the <keyword id="136502" type="ORGANIZATION" weightage="60" keywordseo="FOMC">FOMC</keyword> takes a more firmly backward-looking interpretation of average inflation targeting than we had assumed," Goldman Sachs Economics Research said in a note. "With average inflation over the cycle already on track to exceed 2% by this year, this interpretation appears to lower the future inflation bar for liftoff."Here's where US indexes stood at the 9:30 a.m. open on Thursday: <ul><li><a href="https://markets.businessinsider.com/index/s&amp;p_500?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingestedium=ingest" target="_blank" rel="noopener">S&amp;P 500</a>: 4,225.72, up 0.05%</li><li><a href="https://markets.businessinsider.com/index/dow_jones?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingestm=ingest" target="_blank" rel="noopener">Dow Jones industrial average</a>: 34,064.15, up 0.09% (30.48 points)</li><li><a href="https://markets.businessinsider.com/index/nasdaq_composite?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingestm=ingest" target="_blank" rel="noopener">Nasdaq composite</a>: 14,040.97, down 0.01%</li></ul><a href="https://www.businessinsider.com/weekly-jobless-claims-412000-unemployment-filings-labor-market-economic-recovery-2021-6">Weekly jobless claims came in at an unadjusted 412,000 last week</a>, according to the <a href="https://www.dol.gov/ui/data.pdf">Labor Department</a>. The median estimate from economists surveyed by Bloomberg was for 370,000 claims. The reading snaps six straight weeks of declines that had pulled claims to several pandemic-era lows."While an upward move in jobless claims is not necessarily what we want to see on the economic recovery front, it's still a pretty low number for the pandemic-era and jobless claims have been marching steadily lower since early spring," Mike Loewengart, managing director of investment strategy at E-Trade Financial, said.A boost in jobless claims, however, means that the Fed could be less likely to raise rates faster than the market is anticipating, he said.Meanwhile, <a href="https://markets.businessinsider.com/stocks/cvac-stock?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">CureVac</a> <a href="https://markets.businessinsider.com/news/stocks/curevac-stock-price-covid-19-vaccine-shot-fails-clinical-trial-2021-6-1030531320">tumbled by as much as 50%</a><a href="https://markets.businessinsider.com/stocks/cvac-stock?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener"></a> after the German pharmaceutical firm said its <a href="https://www.businessinsider.com/curevac-vaccine-efficacy-late-stage-trial-covid-bill-gates-2021-4?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">COVID-19 vaccine candidate failed</a> in a clinical trial.In cryptocurrencies, bitcoin was trading slightly lower at around $38,725. The cryptocurrency has been trading sideways following the <a href="https://markets.businessinsider.com/currencies/news/crypto-market-value-47-percent-lost-7-days-2021-5-1030447473?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">massive crash in May</a> but reclaimed <a href="https://markets.businessinsider.com/currencies/news/bitcoin-price-elon-musk-tesla-resume-crypto-payments-clean-energy-2021-6-1030518811?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">$40,000 this week</a>.Last month's massive selloff slashed bitcoin's market capitalization by almost 30% to $766 billion.The benchmark 10-year Treasury yield edged lower to 1.553% from Wednesday's 1.569%.Oil prices slipped. <a href="https://markets.businessinsider.com/commodities/oil-price?type=wti?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingestm=ingest" target="_blank" rel="noopener">West Texas Intermediate crude</a> fell 0.47% to $71.81. <a href="https://markets.businessinsider.com/commodities/oil-price?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingestce=markets&amp;utm_medium=ingest" target="_blank" rel="noopener">Brent crude</a>, oil's international benchmark, ticked lower by 0.63%, to $73.92 per barrel.<a href="https://markets.businessinsider.com/commodities/gold-price?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingestm=ingest" target="_blank" rel="noopener">Gold</a> dropped 1.92%, to $1,783.54. The precious metal tumbled on the Fed's accelerated rate-hike projections.

US stocks mixed as investors digest the Fed's accelerated interest-rate hike guidance

<a href="https://newsletter.businessinsider.com/join/4np/10-things-opening-bell&amp;hash=8122c716833601fc1471f79af063b104?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingestedium=ingest" target="_blank" rel="noopener">Welcome to 10 Things Before the Opening Bell. Sign up here to get this email in your inbox every morning.</a>For the biggest stories in politics, <a href="https://newsletter.businessinsider.com/join/10-things-in-politics?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">sign up here for 10 Things in Politics You Need to Know Today</a> - launching soon!Here's what you need to know before <keyword id="31671" type="CITY" weightage="100" keywordseo="markets">markets</keyword> open.1. Global stocks retreat as caution resurfaces. <a href="https://markets.businessinsider.com/news/stocks/stock-market-today-indices-ease-after-huge-november-rally-2020-11-1029848017">See how markets are reacting</a> today.2. S&amp;P Global strikes deal to buy IHS Markit for $44 billion. The mega-deal marks the <a href="https://markets.businessinsider.com/news/stocks/sp-global-takeover-deal-ihs-markit-wsj-2020-11-1029847879">largest transaction on Wall Street this year</a>.3. Airbnb and DoorDash target higher valuations for their IPOs. Both companies are on track for the <a href="https://markets.businessinsider.com/news/stocks/airbnb-and-doordash-target-higher-valuations-for-december-ipo-2020-11-1029848143">most anticipated market debuts</a> this year scheduled for mid-December.4. How the US economy could transform after Biden's appointment of Janet Yellen. <a href="https://www.businessinsider.com/janet-yellen-treasury-secretary-impact-on-economy-policy-biden-stimulus-2020-11">Here's how Yellen's decades of policymaking experience</a> hint at how she will lead the US Treasury through the economic recovery.5. Mohamed El-Erian cautioned investors about rising bankruptcy rates. He warned that the <a href="https://markets.businessinsider.com/news/stocks/bond-market-economic-outlook-mohamed-el-erian-bankruptcies-vulnerable-2020-11-1029846711">interim journey to a vaccine will be a difficult time</a>, particularly for investors in high-yield credit. 6. <a href="https://markets.businessinsider.com/earnings-calendar#date=11/30/2020&amp;name=&amp;countries=&amp;eventtypes=103,99&amp;tab=L103,99&amp;tab=L">Earnings expected</a>. Zoom and CureVac are highlights.7. <a href="https://markets.businessinsider.com/economic-calendar">On the data docket</a>. Pending home sales, the US 3-month and 6-month bill auctions, and CFTC positioning data are due.8. Goldman Sachs revealed a list of underappreciated stocks poised to break out in 2021. The firm says these <a href="https://www.businessinsider.com/stock-picks-to-buy-high-upside-investment-names-2021-goldman-2020-11?r=opening-bell" target="_blank" rel="noopener">16 picks have at least 20% upside</a>.9. We interviewed an ESG investor whose fund is beating 98% of peers this year. Di Zhou <a href="https://www.businessinsider.com/investing-strategy-how-to-pick-esg-stocks-di-zhou-2020-11?r=opening-bell" target="_blank" rel="noopener">shares her process for selecting winning stocks</a> and explains why Alibaba is her biggest holding.10. A Warren Buffett expert explains the billionaire's latest moves. <a href="https://www.businessinsider.com/warren-buffett-berkshire-hathaway-pharma-costco-jpmorgan-buybacks-john-longo-2020-11?r=opening-bell" target="_blank" rel="noopener">Dr. John Longo dishes on Buffett's big bet on pharma</a>, and his decision to dump Costco and JPMorgan.

10 things you need to know before the opening bell

British-Swedish biopharmaceutical firm AstraZeneca has in partnership with the <keyword id="150557" type="COMPANY" weightage="20" keywordseo="University-of-Oxford">University of Oxford</keyword> rolled out human trials for booster shots against Beta Covid variant. The booster shot, named AZD2816, will be administered to individuals who have previously been fully vaccinated with two doses of AstraZeneca vaccine/Vaxzervia or an mRNA vaccine, at least three months after their last injection. In non-vaccinated individuals, AZD2816 will be given as two doses, four or twelve weeks apart, or given as a second dose following a first dose of AstraZeneca vaccine/Vaxzervia --four weeks apart, the company said in a statement on Sunday. AZD2816 has been designed using the same adenoviral vector platform as AstraZeneca vaccine/ Vaxzervia, with minor genetic alterations to the spike protein based on the Beta (B1351) variant, first identified in South Africa. The study aims to enroll 2,250 participants from the UK, South Africa, Brazil and Poland to build immunity against the Beta Covid variant. "Testing booster doses of existing vaccines and new variant vaccines is important to ensure we are best prepared to stay ahead of the pandemic coronavirus, should their use be needed," said Professor Sir Andrew J. Pollard, chief investigator and director of the Oxford Vaccine Group, in the statement. Initial data from the trial is expected later this year and, once available, will be submitted to regulators for assessment as a next-generation booster vaccine and through an expedited regulatory pathway, the company said. "The Beta variant vaccine contains 10 changes across the spike protein, many of which are also seen in other variants of concern, and which lead to effects such as, reduced ability of antibodies induced against the original virus to block cell entry (K417N, E484K, N501Y), increased infectivity compared to the original virus (D614G); reduced sensitivity of neutralising antibodies to the original virus (L452R)," the company said. Besides these minor modifications, the two AZD2816 and AstraZeneca vaccine/ Vaxzervia vaccines are the same, it noted. In May, the UK launched a clinical trial that aimed to assess the efficacy of a third 'booster' dose of seven different Covid-19 vaccines -- Oxford-AstraZeneca, Pfizer-BioNTech, <keyword id="4912868" type="LOCATION" weightage="20" keywordseo="moderna">Moderna</keyword>, <keyword id="323030" type="LOCATION" weightage="20" keywordseo="Novavax">Novavax</keyword>, Valneva, Janssen and Curevac -- on patients immune responses. It costs 19.3 million pound and is being funded by the UK government and led by the University Hospital Southampton NHS Foundation Trust. Meanwhile, the US Centers for Disease Control and Prevention has noted that there is currently no data to support that a Covid-19 vaccine booster shot is needed for the general population. But, an extra dose may be needed for more-vulnerable groups, such as older adults or organ transplant patients. Both <keyword id="44612" type="LOCATION" weightage="20" keywordseo="Pfizer">Pfizer</keyword> and Moderna are investigating a third dose of Covid vaccine, while <keyword id="92247" type="COMPANY" weightage="20" keywordseo="Johnson-Johnson">Johnson &amp; Johnson</keyword> is studying the need for a second dose to raise protection against the virus, the report said. The US NIH's National Institute of Allergy and Infectious Disease, or NIAID, is also conducting a clinical trial to understand whether a third shot of a Moderna vaccine could be given after a person initially received two shots of Pfizer, or one shot of Johnson &amp; Johnson, the report added. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/startups/news/tiger-global-overtakes-sequoia-as-the-top-investor-in-indian-unicorns-in-2021-cracks-15-deals-this-year-so-far/articleshow/83912624.cms">Tiger Global overtakes Sequoia as the top investor in Indian unicorns in 2021, cracks 15 deals this year so far</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/kims-ipo-listed-in-stock-market-at-over-20-premium/articleshow/83912694.cms">KIMS IPO: Stock listed at over 20% premium, loses initial gains after soaring to ₹1059 per share</a>

You Searched For "curevac stock" and got 8 results

German biotech CureVac's stock plunges 50% after its COVID-19 vaccine candidate failed a clinical trial

Shalini Nagarajan

Bill Gates-backed CureVac jumps 18% on report it's in advanced talks with the EU for 225 million doses of its potential COVID-19 vaccine

Carmen Reinicke

This Bill Gates-backed coronavirus vaccine developer has skyrocketed 431% in just 2 days after going public

Carmen Reinicke

CureVac's COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotech

Andrew Dunn

COVID-19 vaccine tracker: German CureVac shows an immune response, Aspen Pharmacare and J&J sign pact to make vaccine in South Africa

BI India Bureau

US stocks mixed as investors digest the Fed's accelerated interest-rate hike guidance

Isabelle Lee

10 things you need to know before the opening bell

Shalini Nagarajan

AstraZeneca partners with Oxford university to roll out human trials for COVID-19 booster shots against Beta-variant

IANS

Popular Keywords

Buying Guides